Literature DB >> 15526155

Galactokinase: structure, function and role in type II galactosemia.

H M Holden1, J B Thoden, D J Timson, R J Reece.   

Abstract

The conversion of beta- D-galactose to glucose 1-phosphate is accomplished by the action of four enzymes that constitute the Leloir pathway. Galactokinase catalyzes the second step in this pathway, namely the conversion of alpha- D-galactose to galactose 1-phosphate. The enzyme has attracted significant research attention because of its important metabolic role, the fact that defects in the human enzyme can result in the diseased state referred to as galactosemia, and most recently for its utilization via 'directed evolution' to create new natural and unnatural sugar 1-phosphates. Additionally, galactokinase-like molecules have been shown to act as sensors for the intracellular concentration of galactose and, under suitable conditions, to function as transcriptional regulators. This review focuses on the recent X-ray crystallographic analyses of galactokinase and places the molecular architecture of this protein in context with the extensive biochemical data that have accumulated over the last 40 years regarding this fascinating small molecule kinase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15526155     DOI: 10.1007/s00018-004-4160-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  23 in total

Review 1.  The structural biology of enzymes involved in natural product glycosylation.

Authors:  Shanteri Singh; George N Phillips; Jon S Thorson
Journal:  Nat Prod Rep       Date:  2012-06-12       Impact factor: 13.423

2.  Molecular simulation and docking studies of Gal1p and Gal3p proteins in the presence and absence of ligands ATP and galactose: implication for transcriptional activation of GAL genes.

Authors:  Sanjay K Upadhyay; Yellamraju U Sasidhar
Journal:  J Comput Aided Mol Des       Date:  2012-05-26       Impact factor: 3.686

3.  Discovery of novel inhibitors of human galactokinase by virtual screening.

Authors:  Xin Hu; Ya-Qin Zhang; Olivia W Lee; Li Liu; Manshu Tang; Kent Lai; Matthew B Boxer; Matthew D Hall; Min Shen
Journal:  J Comput Aided Mol Des       Date:  2019-02-26       Impact factor: 3.686

4.  Altered cofactor binding affects stability and activity of human UDP-galactose 4'-epimerase: implications for type III galactosemia.

Authors:  Thomas J McCorvie; Ying Liu; Andrew Frazer; Tyler J Gleason; Judith L Fridovich-Keil; David J Timson
Journal:  Biochim Biophys Acta       Date:  2012-05-18

5.  Proliferation of sphere-forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967

6.  The effect of a Pro²⁸Thr point mutation on the local structure and stability of human galactokinase enzyme-a theoretical study.

Authors:  Balázs Jójárt; Milán Szori; Róbert Izsák; István Marsi; Aranka László; Imre G Csizmadia; Béla Viskolcz
Journal:  J Mol Model       Date:  2011-01-25       Impact factor: 1.810

Review 7.  Hsp90 mediates the crosstalk between galactose metabolism and cell morphology pathways in yeast.

Authors:  Rajaneesh Karimpurath Gopinath; Jun-Yi Leu
Journal:  Curr Genet       Date:  2016-05-21       Impact factor: 3.886

8.  Galactokinase is a novel modifier of calcineurin-induced cardiomyopathy in Drosophila.

Authors:  Teresa E Lee; Lin Yu; Matthew J Wolf; Howard A Rockman
Journal:  Genetics       Date:  2014-07-31       Impact factor: 4.562

9.  pH-rate profiles support a general base mechanism for galactokinase (Lactococcus lactis).

Authors:  Laurie A Reinhardt; James B Thoden; Greg S Peters; Hazel M Holden; W W Cleland
Journal:  FEBS Lett       Date:  2013-07-19       Impact factor: 4.124

10.  Metabolic engineering strategies for the improvement of cellulase production by Hypocrea jecorina.

Authors:  Christian P Kubicek; Marianna Mikus; André Schuster; Monika Schmoll; Bernhard Seiboth
Journal:  Biotechnol Biofuels       Date:  2009-09-01       Impact factor: 6.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.